yahoo_financeOriginal article
Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma
Phase 3positivePositive
AI Analysis
Summary
Roche Holding announced that its Phase III trial met its primary endpoint in follicular lymphoma, representing positive clinical trial data for the company.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Primary endpoint met
Importance:7/10
Sentiment:
0.75
Phase 3Follicular LymphomaPrimary Endpoint MetClinical Trial
Related Companies
Read the original article
Published by yahoo_finance on September 17, 2026 3:11 PM